Frank\u00adfurt a.M. \u2014 McDer\u00admott Will & Emery, as tran\u00adsac\u00adtion coun\u00adsel, advi\u00adses the issuer APONTIS PHARMA AG, its main share\u00adhol\u00adder, the invest\u00adment company Para\u00adgon Part\u00adners, as well as the joint book\u00adrun\u00adners Hauck & Aufh\u00e4u\u00adser and M.M.Warburg on the IPO at the Frank\u00adfurt Stock Exchange.<\/p>\n
The place\u00adment price for the IPO was set at 19.00 euros per share. The place\u00adment volume totals 101 million euros. A total of 5,290,000 shares were placed with inves\u00adtors as part of the IPO, which also included a U.S. tran\u00adche in accordance with Rule 144A of the U.S. Secu\u00adri\u00adties Act. The place\u00adment includes 2,000,000 new shares from a cash capi\u00adtal increase as well as 1,600,000 exis\u00adting shares in connec\u00adtion with a base deal, 1,000,000 exis\u00adting shares in connec\u00adtion with a top-up option and 690,000 exis\u00adting shares in connec\u00adtion with an over-allot\u00adment option from the holdings of the main share\u00adhol\u00adder Para\u00adgon Part\u00adners. The first day of trading on the Frank\u00adfurt Stock Exch\u00adange is sche\u00addu\u00adled for May 11, 2021. The exis\u00adting share\u00adhol\u00adders Para\u00adgon Part\u00adners and the manage\u00adment of APONTIS PHARMA will remain share\u00adhol\u00adders in the company after the place\u00adment with a stake of 31% and 7%, respectively.<\/p>\n
APONTIS PHARMA AG is a leading phar\u00admaceu\u00adti\u00adcal company for single pills in the German market. The Company intends to use the net proceeds from the issu\u00adance of the new shares prima\u00adrily for selec\u00adted invest\u00adments in the deve\u00adlo\u00adp\u00adment of new single pills, acce\u00adle\u00adra\u00adting the deve\u00adlo\u00adp\u00adment and licen\u00adsing of the exis\u00adting near-term product pipe\u00adline, and expan\u00adding marke\u00adting and sales acti\u00advi\u00adties to capture addi\u00adtio\u00adnal market share and product acquisitions.<\/p>\n
McDer\u00admott provi\u00added compre\u00adhen\u00adsive capi\u00adtal markets legal advice to all parties invol\u00adved. The McDer\u00admott team was also respon\u00adsi\u00adble for the corpo\u00adrate struc\u00adtu\u00adring in the run-up to the IPO.<\/p>\n
Advi\u00adsors APONTIS, Para\u00adgon Part\u00adners and banks Hauck & Aufh\u00e4u\u00adser and M.M.Warburg:<\/strong> Frank\u00adfurt a.M. \u2014 McDer\u00admott Will & Emery, as tran\u00adsac\u00adtion coun\u00adsel, advi\u00adses the issuer APONTIS PHARMA AG, its main share\u00adhol\u00adder, the invest\u00adment company Para\u00adgon Part\u00adners, as well as the joint book\u00adrun\u00adners Hauck & Aufh\u00e4u\u00adser and M.M.Warburg on the IPO at the Frank\u00adfurt Stock Exch\u00adange. The place\u00adment price for the IPO was set at 19.00 euros per [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":37360,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1365,1366,1367,1368,1369,1371,1372],"tags":[],"class_list":["post-43472","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-private-equity-en","category-news-en","category-lawyers-tax-advisors-auditors-en","category-lawyers-tax-consultants-auditors","category-investors","category-deals-en","category-consultant","news-category-deals-news-en","news-category-private-equity-news-en"],"yoast_head":"\n
\nMcDer\u00admott Will & Emery, Frank\u00adfurt a.M.\/D\u00fcsseldorf<\/strong>
\nCapi\u00adtal Markets\/IPO Work\u00adstream: Simon Wei\u00df (Project Coor\u00addi\u00adna\u00adtion; Capi\u00adtal Markets), Joseph W. Marx (US Capi\u00adtal Markets; joint lead), Gregory M. Weig\u00adand (Miami), Edwin C. Lauren\u00adson (Coun\u00adsel, San Fran\u00adcisco; both US Law), Dr. Deniz Tschamm\u00adler (Munich), Dr. Monika Rich\u00adter (both Coun\u00adsel, both Life Scien\u00adces); Asso\u00adcia\u00adtes: Dr. Marion von Gr\u00f6n\u00adheim, Isabelle Suzanne M\u00fcller, Chris\u00adtoph Sch\u00e4\u00adfer, Ardalan Zargari (Staff Attor\u00adney); Corpo\u00adrate Work\u00adstream: Dr. Phil\u00adipp Gren\u00adze\u00adbach (Lead), Dr. Thomas Gennert (both Corpo\u00adrate, both D\u00fcssel\u00addorf); Asso\u00adciate: Tom Sch\u00e4fer<\/p>\n","protected":false},"excerpt":{"rendered":"